CLINICAL RELEVANCE MAKES ALL THE DIFFERENCE: Leveraging Orthotopic PDX Models in Translational Oncology
- Accurately predict drug response, drug resistance and metastatic proliferation
- Reliably mirror the behavior of cancer in their human counterparts, at an accelerated pace — making them clinically relevant patient avatars for evaluating cancer therapies
- How the tumor microenvironment factors into selecting optimal cancer model(s) for your preclinical in vivo pharmacology study
- How orthotopic PDX models combined with live in situ imaging (like mouse MRI) can accurately predict drug response, drug resistance and metastatic proliferation
- About the need for clinically relevant solid tumor models for the translation of T cell-based therapies into the clinic
- How orthotopic PDX models can be used to validate artificial intelligence predictions in drug discovery and development
- How personalized orthotopic PDX of an individual’s cancer can be used as a functional testing platform
Register to Attend
Dr. Jonathan Nakashima
CSO, Certis Oncology
Dr. Jonathan Nakashima is the CSO of Certis Oncology, where he oversees the R&D initiatives, patient-directed orthotopic PDX pharmacology studies, and the development and implementation of translational oncology assays for drug development. Dr. Nakashima has more than 15 years of experience developing preclinical oncology models. Under a California Institute for Regenerative Medicine fellowship, he received his doctorate in Molecular and Medical Pharmacology at UCLA, where he developed genetically engineered and patient-derived xenograft models to study cancers of the central and peripheral nervous systems. He continued with his post-doctoral training in the Department of Neurobiology, where he received a Kirschstein National Research Service Award to study the cell interactions in the brain-tumor microenvironment.
Visit Certis Oncology.